Editas Medicine Names James C. Mullen as Chairman of the Board of Directors – PharmiWeb.com (press release)
|
Editas Medicine Names James C. Mullen as Chairman of the Board of Directors
PharmiWeb.com (press release) As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the … |
